Redeye maintains a positive view on LIDDS and its NanoZolid® drug delivery tool, after today's news that NZ-TLR9 releases the active substance slowly over 6 weeks and results in a strong antitumoral response in mice-models. Investors can look forward to the start of the clinical studies in H2 2021, which will be a trigger for the stock.